{
  "schemaVersion": 1,
  "organisationId": "O-afad5fb2425a46539206f303a1718950",
  "slug": "recordati",
  "name": "RECORDATI",
  "updatedAt": "2026-10-04T14:42:59.202362Z",
  "sections": [
    {
      "type": "OVERVIEW",
      "text": "Recordati is an international pharmaceutical group, established in 1926, operating across Specialty & Primary Care and Rare Diseases. Its activities include research and development, manufacturing and commercialization, with products including Zanidip, Eligard, Isturisa and Qarziba. The company describes its purpose as helping people “unlock the full potential of their lives.” [P105172246][https://recordati.com/company-our-story/]\n\nFor FY2025, Recordati reported net revenue of €2,618.4 million and approximately 4,700 employees. It operates in around 150 countries across EMEA, the Americas and APAC. [T8841092][https://annualreport.recordati.com/who-we-are/]\n[P105172246][T8841092][T6952822][https://recordati.com/company-our-story/][https://annualreport.recordati.com/who-we-are/]",
      "updatedAt": "2026-10-04T14:42:59.202362Z"
    },
    {
      "type": "PRODUCTS",
      "text": "Recordati’s Specialty & Primary Care portfolio includes cardiovascular products Zanidip/Zanipress (lercanidipine, alone or combined with enalapril), Seloken/Logimax (metoprolol-based products), Livazo (pitavastatin) and Vazkepa (icosapent ethyl). Its urology and uro-oncology products include Urorec (silodosin) and Avodart and related combinations (dutasteride, alone or with tamsulosin) for benign prostatic hyperplasia, and Eligard (leuprorelin acetate), a subcutaneous depot injection for prostate cancer; the company also reports a pre-connected syringe system for Eligard. [P23365841][P14447839] Rare-disease products include Isturisa (osilodrostat), which inhibits cortisol synthesis and is used for Cushing’s syndrome, and Signifor/Signifor LAR (pasireotide) for pituitary disorders including Cushing’s disease and acromegaly. Hema-oncology products include Qarziba (dinutuximab beta), an anti-GD2 antibody for specified patients with high-risk neuroblastoma; Sylvant (siltuximab), an anti-IL-6 antibody for idiopathic multicentric Castleman disease; Enjaymo (sutimlimab), a C1s complement inhibitor for cold agglutinin disease; and Fotivda (tivozanib), an oral VEGF-receptor 1/2/3 tyrosine-kinase inhibitor for advanced renal-cell carcinoma. [P58127960][P53459012][P13844081][T8680885]\n\nOther named rare-disease products include Carbaglu (carglumic acid), Normosang/Panhematin (human hemin), Cystadane (betaine), Cystadrops and Cystagon (cysteamine products), Juxtapid (lomitapide), Ledaga (chlormethine), IV Pedea/Neoprofen (ibuprofen), and Maapliv (a branched-chain-amino-acid-free amino-acid formulation). [T3331076] In FY2025, reported product revenues included Isturisa €262.8 million, Qarziba €159.3 million, Enjaymo €146.3 million, Signifor/Signifor LAR €131.3 million and Eligard €129.4 million; Specialty & Primary Care and Rare Diseases were also reported by therapeutic area. [T6952822][T11218637] The latest portfolio mix located, for Q1 2026, allocated pharmaceutical revenue to cardiovascular 15.9%, urology 14.6%, other Specialty & Primary Care 12.2%, gastrointestinal 9.7%, cough & cold 4.2%, pharmaceutical chemicals 2.3%, Rare Diseases endocrinology 16.9%, hema-oncology 15.9% and metabolic 8.2%. [T4050053]\n[P23365841][P14447839][P58127960][P53459012][P13844081][T8680885][T3331076][T6952822][T11218637][T4050053]",
      "updatedAt": "2026-10-04T14:42:59.202362Z"
    },
    {
      "type": "GEOGRAPHY",
      "text": "Recordati reports commercial activity in about 150 markets across EMEA, the Americas and APAC. In Q1 2026, pharmaceutical revenue was €696.8 million: the U.S. accounted for €151.6 million (21.8%), Italy €95.9 million (13.8%), Spain €61.8 million (8.9%), France €47.9 million (6.9%), Germany €41.2 million (5.9%) and Türkiye €40.4 million (5.8%). Other reported areas were Russia, other CIS countries and Ukraine (5.7%); Portugal (2.6%); North Africa (1.8%); Other C.E.E. (7.5%); Other W. European countries (6.4%); and other international sales (13.1%). Chemicals were reported separately. [T3734940][T10942573]\n\nThe group’s disclosed subsidiaries and offices span Europe, including Italy, Spain, France, Germany, the UK, Portugal, Greece, Sweden, Czechia, Poland, Russia, Ukraine and Türkiye; North Africa; the Americas, including the U.S., Brazil, Canada, Mexico, Colombia and Argentina; and Asia-Pacific and the Middle East, including China, Japan, South Korea, Australia, the UAE and Saudi Arabia. Milan is the headquarters. [T65781][T4912503][T14118618][https://recordati.com/our-offices/]\n\nRecordati reported 10 production sites for 2025, with manufacturing locations including Campoverde in Italy, Cork in Ireland, Utebo in Spain, Tunisia and Türkiye; the Pardubice plant ceased activities at the end of 2025. The company reported 4,693 employees for FY2025, but the cited disclosure provides no geographic breakdown of headcount. [https://annualreport.recordati.com/who-we-are/][P19616196][T6479780][T6830837][T4218118][P6796614][T6383011]\n[T3734940][T10942573][T65781][T4912503][T14118618][https://recordati.com/our-offices/][https://annualreport.recordati.com/who-we-are/][P19616196][T6479780][T6830837][T4218118][P6796614][T6383011][https://recordati.com/our-offices/][https://annualreport.recordati.com/who-we-are/]",
      "updatedAt": "2026-10-04T14:42:59.202362Z"
    },
    {
      "type": "SEGMENTS",
      "text": "For FY 2025, Recordati reported two business segments. **Specialty & Primary Care (SPC)** generated €1,536.9 million, approximately 58.7% of consolidated net revenue (€2,618.4 million). Its portfolio focuses on established treatments for common conditions, with reported therapeutic areas including urology, cardiovascular, gastrointestinal, cough and cold, and other treatment areas; the accounts also include pharmaceutical chemicals within SPC revenue. [T7151789][T11218637][https://recordati.com/speciality-and-primary-care/]\n\n**Rare Diseases** generated €1,081.4 million, approximately 41.3% of consolidated net revenue. The company reports three franchises: Endocrinology, Hema-Oncology, and Metabolic (listed in the therapeutic-area breakdown as “Metabolic and other areas”). [T7151789][T11218637][https://recordati.com/rare-diseases/]\n\nThe two segments are the main business segmentation; therapeutic areas provide an additional breakdown of sales rather than further business segments. Percentages are approximate, calculated from FY 2025 segment revenues and consolidated net revenue. [T7151789][T11218637]\n[T7151789][T7151789][T7151789][T11218637][https://recordati.com/speciality-and-primary-care/][https://recordati.com/rare-diseases/]",
      "updatedAt": "2026-10-04T14:42:59.202362Z"
    },
    {
      "type": "HISTORY",
      "text": "Recordati was founded in 1926 by Giovanni Recordati as Laboratorio Farmacologico Reggiano in Correggio. The company moved its headquarters to Milan in 1953 and was listed on the Italian Stock Exchange in 1984. [https://recordati.com/company-our-story/][https://recordati.com/milestones-and-announcements/]\n\nInternational expansion included the acquisitions of Doms Adrian and Bouchara in 1999–2000. In 2007, the acquisition of Orphan Europe marked Recordati’s entry into rare diseases. [https://recordati.com/milestones-and-announcements/]\n\nIn 2018, the Recordati family agreed to transfer its controlling holding company, Fimei, to a consortium controlled by CVC, changing the company’s ownership. [https://recordati.com/wp-content/uploads/2023/06/annual-report-2018-1-1.pdf] Around 2019–2020, Recordati expanded its rare-disease business into endocrinology, acquiring global rights to Signifor and osilodrostat; Isturisa received EU approval in January 2020. [https://recordati.com/milestones-and-announcements/][https://recordati.com/wp-content/uploads/2023/06/closing-signifor-1.pdf][https://recordati.com/wp-content/uploads/2023/06/preliminary-2019-results-and-2020-targets.pdf]\n\nRecordati announced the acquisition of EUSA Pharma in 2021 and completed it in 2022, broadening its rare-disease and niche-oncology portfolio. In 2024, it agreed to acquire and then completed the acquisition of global rights to Enjaymo. [https://recordati.com/recordati-to-acquire-eusa-pharma-uk-ltd-a-global-specialty-pharmaceutical-company-focused-on-rare-and-niche-oncology-diseases-2021-12-03-073200-business-financial-news/][https://recordati.com/wp-content/uploads/2023/06/eusa-closing-pr-1.pdf][https://recordati.com/wp-content/uploads/2024/10/PR_Acquisition-of-global-rights-to-Enjaymo.pdf][https://recordati.com/wp-content/uploads/2024/11/Press-Release_Enjaymo-Acquisition-Completion.pdf]\n[https://recordati.com/company-our-story/][https://recordati.com/milestones-and-announcements/][https://recordati.com/wp-content/uploads/2023/06/annual-report-2018-1-1.pdf][https://recordati.com/wp-content/uploads/2023/06/closing-signifor-1.pdf][https://recordati.com/wp-content/uploads/2023/06/preliminary-2019-results-and-2020-targets.pdf][https://recordati.com/recordati-to-acquire-eusa-pharma-uk-ltd-a-global-specialty-pharmaceutical-company-focused-on-rare-and-niche-oncology-diseases-2021-12-03-073200-business-financial-news/][https://recordati.com/wp-content/uploads/2023/06/eusa-closing-pr-1.pdf][https://recordati.com/wp-content/uploads/2024/10/PR_Acquisition-of-global-rights-to-Enjaymo.pdf][https://recordati.com/wp-content/uploads/2024/11/Press-Release_Enjaymo-Acquisition-Completion.pdf]",
      "updatedAt": "2026-10-04T14:42:59.202362Z"
    }
  ],
  "sources": [
    {
      "id": "P105172246",
      "href": "https://app.finbar.com/go?id=P105172246",
      "label": "RECORDATI — Presentation (2025 Y), p24",
      "documentId": "D-10071ea3889c47eeb1616bfc3b64e5a7",
      "page": 24
    },
    {
      "id": "https://recordati.com/company-our-story/",
      "href": "https://recordati.com/company-our-story/",
      "label": "recordati.com"
    },
    {
      "id": "T8841092",
      "href": "https://app.finbar.com/go?id=T8841092",
      "label": "RECORDATI — Presentation (2026 Q 1), p12",
      "documentId": "D-cc32479a92024118948c927142cd1a21",
      "page": 12
    },
    {
      "id": "https://annualreport.recordati.com/who-we-are/",
      "href": "https://annualreport.recordati.com/who-we-are/",
      "label": "annualreport.recordati.com"
    },
    {
      "id": "T6952822",
      "href": "https://app.finbar.com/go?id=T6952822",
      "label": "RECORDATI — Presentation (2025 Y), p17",
      "documentId": "D-10071ea3889c47eeb1616bfc3b64e5a7",
      "page": 17
    },
    {
      "id": "P23365841",
      "href": "https://app.finbar.com/go?id=P23365841",
      "label": "RECORDATI — Full financial report (2025 Y), p99",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 99
    },
    {
      "id": "P14447839",
      "href": "https://app.finbar.com/go?id=P14447839",
      "label": "RECORDATI — Full financial report (2025 Y), p29",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 29
    },
    {
      "id": "P58127960",
      "href": "https://app.finbar.com/go?id=P58127960",
      "label": "RECORDATI — Full financial report (2025 Y), p35",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 35
    },
    {
      "id": "P53459012",
      "href": "https://app.finbar.com/go?id=P53459012",
      "label": "RECORDATI — Full financial report (2025 Y), p53",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 53
    },
    {
      "id": "P13844081",
      "href": "https://app.finbar.com/go?id=P13844081",
      "label": "RECORDATI — Full financial report (2025 Y), p99",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 99
    },
    {
      "id": "T8680885",
      "href": "https://app.finbar.com/go?id=T8680885",
      "label": "RECORDATI — Full financial report (2025 Y), p35",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 35
    },
    {
      "id": "T3331076",
      "href": "https://app.finbar.com/go?id=T3331076",
      "label": "RECORDATI — Full financial report (2025 Y), p36",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 36
    },
    {
      "id": "T11218637",
      "href": "https://app.finbar.com/go?id=T11218637",
      "label": "RECORDATI — Full financial report (2025 Y), p249",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 249
    },
    {
      "id": "T4050053",
      "href": "https://app.finbar.com/go?id=T4050053",
      "label": "RECORDATI — Presentation (2026 Q 1), p16",
      "documentId": "D-cc32479a92024118948c927142cd1a21",
      "page": 16
    },
    {
      "id": "T3734940",
      "href": "https://app.finbar.com/go?id=T3734940",
      "label": "RECORDATI — Presentation (2026 Q 1), p9",
      "documentId": "D-cc32479a92024118948c927142cd1a21",
      "page": 9
    },
    {
      "id": "T10942573",
      "href": "https://app.finbar.com/go?id=T10942573",
      "label": "RECORDATI — Presentation (2026 Q 1), p16",
      "documentId": "D-cc32479a92024118948c927142cd1a21",
      "page": 16
    },
    {
      "id": "T65781",
      "href": "https://app.finbar.com/go?id=T65781",
      "label": "RECORDATI — Full financial report (2025 Y), p272",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 272
    },
    {
      "id": "T4912503",
      "href": "https://app.finbar.com/go?id=T4912503",
      "label": "RECORDATI — Full financial report (2025 Y), p273",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 273
    },
    {
      "id": "T14118618",
      "href": "https://app.finbar.com/go?id=T14118618",
      "label": "RECORDATI — Full financial report (2025 Y), p274",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 274
    },
    {
      "id": "https://recordati.com/our-offices/",
      "href": "https://recordati.com/our-offices/",
      "label": "recordati.com"
    },
    {
      "id": "P19616196",
      "href": "https://app.finbar.com/go?id=P19616196",
      "label": "RECORDATI — Full financial report (2025 Y), p45",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 45
    },
    {
      "id": "T6479780",
      "href": "https://app.finbar.com/go?id=T6479780",
      "label": "RECORDATI — Full financial report (2025 Y), p115",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 115
    },
    {
      "id": "T6830837",
      "href": "https://app.finbar.com/go?id=T6830837",
      "label": "RECORDATI — Full financial report (2025 Y), p113",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 113
    },
    {
      "id": "T4218118",
      "href": "https://app.finbar.com/go?id=T4218118",
      "label": "RECORDATI — Full financial report (2025 Y), p114",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 114
    },
    {
      "id": "P6796614",
      "href": "https://app.finbar.com/go?id=P6796614",
      "label": "RECORDATI — Full financial report (2025 Y), p171",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 171
    },
    {
      "id": "T6383011",
      "href": "https://app.finbar.com/go?id=T6383011",
      "label": "RECORDATI — Full financial report (2025 Y), p187",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 187
    },
    {
      "id": "T7151789",
      "href": "https://app.finbar.com/go?id=T7151789",
      "label": "RECORDATI — Full financial report (2025 Y), p249",
      "documentId": "D-305427841a9f472698789bee99c9afa1",
      "page": 249
    },
    {
      "id": "https://recordati.com/speciality-and-primary-care/",
      "href": "https://recordati.com/speciality-and-primary-care/",
      "label": "recordati.com"
    },
    {
      "id": "https://recordati.com/rare-diseases/",
      "href": "https://recordati.com/rare-diseases/",
      "label": "recordati.com"
    },
    {
      "id": "https://recordati.com/milestones-and-announcements/",
      "href": "https://recordati.com/milestones-and-announcements/",
      "label": "recordati.com"
    },
    {
      "id": "https://recordati.com/wp-content/uploads/2023/06/annual-report-2018-1-1.pdf",
      "href": "https://recordati.com/wp-content/uploads/2023/06/annual-report-2018-1-1.pdf",
      "label": "recordati.com"
    },
    {
      "id": "https://recordati.com/wp-content/uploads/2023/06/closing-signifor-1.pdf",
      "href": "https://recordati.com/wp-content/uploads/2023/06/closing-signifor-1.pdf",
      "label": "recordati.com"
    },
    {
      "id": "https://recordati.com/wp-content/uploads/2023/06/preliminary-2019-results-and-2020-targets.pdf",
      "href": "https://recordati.com/wp-content/uploads/2023/06/preliminary-2019-results-and-2020-targets.pdf",
      "label": "recordati.com"
    },
    {
      "id": "https://recordati.com/recordati-to-acquire-eusa-pharma-uk-ltd-a-global-specialty-pharmaceutical-company-focused-on-rare-and-niche-oncology-diseases-2021-12-03-073200-business-financial-news/",
      "href": "https://recordati.com/recordati-to-acquire-eusa-pharma-uk-ltd-a-global-specialty-pharmaceutical-company-focused-on-rare-and-niche-oncology-diseases-2021-12-03-073200-business-financial-news/",
      "label": "recordati.com"
    },
    {
      "id": "https://recordati.com/wp-content/uploads/2023/06/eusa-closing-pr-1.pdf",
      "href": "https://recordati.com/wp-content/uploads/2023/06/eusa-closing-pr-1.pdf",
      "label": "recordati.com"
    },
    {
      "id": "https://recordati.com/wp-content/uploads/2024/10/PR_Acquisition-of-global-rights-to-Enjaymo.pdf",
      "href": "https://recordati.com/wp-content/uploads/2024/10/PR_Acquisition-of-global-rights-to-Enjaymo.pdf",
      "label": "recordati.com"
    },
    {
      "id": "https://recordati.com/wp-content/uploads/2024/11/Press-Release_Enjaymo-Acquisition-Completion.pdf",
      "href": "https://recordati.com/wp-content/uploads/2024/11/Press-Release_Enjaymo-Acquisition-Completion.pdf",
      "label": "recordati.com"
    }
  ]
}